Germany Pharmaceuticals and Healthcare Report Q3 2008 - Companies ... Live-PR.com (Pressemitteilung), Austria - Nov 24, 2008 Boehringer Ingelheim received positive news from the European Commission after their new drug Pradaxa (dabigatran etexilate) gained approval for marketing ...
The Global HIV AIDS Market Outlook to 2012 - New Research Report ... Live-PR.com (Pressemitteilung), Austria - Nov 17, 2008 ... Gilead, BMS, Abbott, Roche, Boehringer Ingelheim, Pfizer, Merck, Barr and Kohl Medical. ? Discover which HIV drug classes have the greatest potential to ...
Thousands of lives lost in treatment delays Plus News, South Africa - Nov 7, 2008 The authors pointed out that the South African government declined the offer of free nevirapine from pharmaceutical manufacturer Boehringer Ingelheim in ...
Brazil Pharmaceuticals and Healthcare Report Q3 2008 - http://www ... Live-PR.com (Pressemitteilung), Austria - Nov 26, 2008 The government declared Gilead?s AIDS drug Tenofovir (disoproxil fumarate) ?in the public interest? in April, indicating it could reject a patent request ...
Foreign Investment in Pharmaceuticals Hampered by Regulations Tempo Interaktif, Indonesia - Nov 6, 2008 However incoming investors are carrying out research in medicines to cure cancer, AIDS, and the avian flu. "They are not our competitors," he told Tempo ...
Recent News and Articles on the Keywords: 0.18 + boehringer + web Related to the article below (Last Update: 8/7/2008)
Tele2Tango launches international discount plan Telecom Paper (subscription), Netherlands - 13 minutes ago Subscribers receive a discounted rate of EUR 0.09 per minute to fixed lines and EUR 0.18 per to mobiles in the designated country. ...
*SHENZHEN B-SHARE INDEX OPENS DOWN 0.18 PTS AT 459.49 華富財經, Hong Kong - Jul 30, 2008 In relation to the stock quote service (the "Quote Service") information, the stock price, trade volume and turnover are provided by The Stock Exchange of ...
BOVESPA: Index falls 0.18%, to 59890 points Gazeta Mercantil, Brazil - Jul 31, 2008 S?O PAULO, 7/31/08 - The S?o Paulo Stock Exchange (Bovespa) reduced the losses seen in the beginning of the session and, a short while ago, fell 0.18%, ...
[PDF]XMM-Newton high-resolution spectroscopy reveals the chemical evolution of M 87 - N Werner, H Boehringer, JS Kaastra, J de Plaa, A … - Arxiv preprint astro-ph/0608177, 2006 - arxiv.org ... area corrections found by one of us (Jacco Vink; more information can be found on
the web- site of the ... Y 1 0.82 ? 0.04 0.23 ? 0.03 0.16 ? 0.02 0.18 ? 0.02 ... -
Critical Duration of Intracellular Ca2+ Response Required for Continuous Translocation and … - T Hirabayashi, K Kume, K Hirose, T Yokomizo, M … - Journal of Biological Chemistry, 1999 - ASBMB ... leukotriene B 4 were generous gifts from Boehringer Ingelheim (Germany ... analysis of
the binding of [ 3 H]WEB 2086 or ... 5 min in the buffer containing 0.18, 1.8, or ...
- AS Prokopowicz III, MP Brown, JM Wildeson, S Jakes … - US Patent 7,125,996, 2006 - Google Patents ... (73) Assignee: Boehringer Ingelheim Pharmaceuticals ...0.18... The seventh edition is available
on CD-ROM and an updated seventh edition is available on the Web at www ...
FRANKFURT - German drugmaker Boehringer Ingelheim's AIDS drug Aptivus helped reduce amounts of the virus in children, according to results of a study, the company said on Monday.
Boehringer said results from a 48-week analysis of the 115-child trial showed that patients achieved a decrease in virologic load, which measures the amount of virus in the blood.
They experienced an increase in so-called CD4+ cells that protect the body against infection.
All but three of the children had undergone other treatments in the past and were infected with strains of the AIDS-causing HIV virus that showed high levels of resistance to other drugs.
Aptivus, or tipranavir, competes with rivals from GlaxoSmithKline, Roche, Pfizer and Merck & Co.
Unlisted Boehringer said in a statement it planned to apply for European approvals next year for the use of tipranavir in HIV-infected children who had received prior treatment with other drugs.
The results of the study were presented at the 16th International AIDS Conference in Toronto, Canada.
Boehringer was recently ousted as Germany's top drugmaker by sales by Bayer, which has acquired rival Schering for about 17 billion euros ($22 billion).